Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by longonMJon Jan 17, 2019 2:58am
101 Views
Post# 29243852

RE:RE:RE:RE:RE:RE:RE:Today looks like another write off

RE:RE:RE:RE:RE:RE:RE:Today looks like another write offHow sure are you that Canopy's top line sales revenue will be close to the analysts consensus estimate of $89 for this reporting quarter?  Especially when none of the other major weed companies came close to their consensus estimates for this quarter so far.  In fact, how sure are you that their sales revenues will even beat Aurora's new high end guidance of $55M?

Especially since Linton acknowledged that a reading of current financials would lead one to question the company' sustainability.  This definitely does not sound like good news to me for the Q3 financials.

krisruna wrote: Q3 earning may not be that terrible.

Analyst are expecting 89 M revenue. ACB guided 50 to 55 M.  Canopy should be higher than this. So, we should be closer to 89 M revenue.

In terms of loss, last Q was 335 M loss. One big item was share based compensation which was 99 M. This Q3 this item will disappear (because stock PPS on 31st Dec was lower than previous 3 months ago. So, loss should be significantly lower.

Bottom Linev - (1) Revene not bad (compared to analyst expectation) and (2) Loss much less than Q2. Thanks.


Bullboard Posts